Envista Holdings heads into its May 19 earnings with a genuinely mixed setup: short interest that has climbed sharply over the past month, options traders leaning bullish, and the Street still split between caution and conviction.
The short interest story is the most notable development in recent weeks. Bears have quietly rebuilt positions from around 4.1% of the float in late March to 6.7% now — a 34% increase in borrowed shares over the past month. The move stalled late this week, with SI pulling back from a peak of 7.1% on May 4 to 6.7% on May 5. That mid-week retreat coincides with a sharp single-session drop of 5.5% in shares short. Whether that's genuine covering or temporary noise ahead of the earnings date remains to be seen. The ORTEX short score of 44, while moderate, has been drifting lower this week from the mid-45s.
Despite the rebuilding short base, the borrow market is not flashing stress. Availability is loose — the lending pool has plenty of room, with borrow costs running at just 0.45% APR, well within normal territory. The 52-week peak on utilization was 18%, and today's reading is a fraction of that. Options traders are even more relaxed. The put/call ratio of 0.17 is slightly below its 20-day average of 0.20, and the z-score is mildly negative. That combination — more shorts in the stock but no urgency in the borrow market and call-leaning options flow — describes a position where bears are rebuilding gradually rather than rushing.
The Street is divided but not dramatically so. The most recent analyst action came from Morgan Stanley on April 24, where Erin Wright raised her Equal-Weight target from $19 to $21. At the same time, Citigroup initiated coverage at Neutral with a $29 target on April 15, and Evercore ISI trimmed its Outperform target from $32 to $30 on April 8. The consensus mean target of around $28.70 sits comfortably above the current price of $26.19, implying roughly 10% upside. Bulls point to the return of implant sales growth and upward guidance revisions on core sales, while bears flag limited margin expansion and EBIT misses. The EV/EBITDA multiple of 11.3x has crept higher by roughly 0.7 points over the past month — a quiet re-rating that hasn't drawn much attention. The 90-day EPS momentum factor ranks in the 81st percentile, a meaningful read that forward estimates have been moving in the right direction.
Historical earnings reactions offer a sharp contrast. February's print triggered a 23% single-day rally — a dramatic outcome after what appears to have been heavily reduced expectations. April 29's release was more modest, with the stock down around 2%. Two very different reactions from two consecutive reports is a reminder that the distribution of outcomes for NVST around earnings remains wide.
With the next report confirmed for May 19, the key tension is whether the short rebuild over the past month reflects genuine fundamental concern or simply a hedge against that earnings uncertainty — and whether options traders' call-side lean will stay intact as the date approaches.
See the live data behind this article on ORTEX.
Open NVST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
